Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-063713
Filing Date
2023-11-14
Accepted
2023-11-14 16:15:27
Documents
64
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ikt-20230930.htm   iXBRL 10-Q 1775890
2 EX-31.1 ikt-ex31_1.htm EX-31.1 14800
3 EX-31.2 ikt-ex31_2.htm EX-31.2 14829
4 EX-32.1 ikt-ex32_1.htm EX-32.1 12031
5 EX-32.2 ikt-ex32_2.htm EX-32.2 12031
  Complete submission text file 0000950170-23-063713.txt   6331545

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ikt-20230930_lab.xml EX-101.LAB 364458
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ikt-20230930_def.xml EX-101.DEF 151546
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ikt-20230930.xsd EX-101.SCH 46670
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ikt-20230930_pre.xml EX-101.PRE 275681
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ikt-20230930_cal.xml EX-101.CAL 34731
58 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20230930_htm.xml XML 1031066
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39676 | Film No.: 231406436
SIC: 2836 Biological Products, (No Diagnostic Substances)